Macrogenics Inc
(NAS:MGNX)
$
4.03
+0.040 (+1%)
Market Cap: 256.16 Mil
Enterprise Value: 138.44 Mil
PE Ratio: 0
PB Ratio: 12.07
GF Score: 47/100 Zymeworks Inc and MacroGenics Inc at Citi BioPharma Conference - Co Panel: Bispecific Panel Transcript
Sep 07, 2022 / 06:40PM GMT
Release Date Price:
$4.23
(+4.19%)
Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst
So let's start. Welcome back, everyone. I think everyone knows me. I'm Yigal Nochomovitz, one of the biotech analyst at Citi. I cover both these distinguished companies. So welcome both of you. Scott Koenig, CEO, MacroGenics; and not [Neal Joseph], Ken from Zymeworks. So welcome both to you.
Scott Koenig
MacroGenics, Inc. - President, CEO & Director
Thank you.
Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst
Great. Great to have you here.
Kenneth H. Galbraith
Zymeworks Inc. - CEO & Chairman of the Board
Pleasure.
Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst
So I think for those who are less familiar with both of your companies, we could just start with a quick 2- to 3-minute overview of the pipeline. What are the -- highlight the key assets, maybe some of the key clinical trials you're
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot